Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reduced by 425,744 shares, marking a 63.01% reduction and a -0.96% impact on the ...

The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...

Cash Runway: Expected to extend beyond 2027. 2seventy bio Inc (NASDAQ:TSVT) successfully completed the sale of its oncology and autoimmune R&D pipeline to Regeneron, streamlining operations. The ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, ...

We issued a press release on our third quarter, 2024 financial results. The press release can be found in the investors and media section of the company's website at 2 seventybio.com. As a reminder, ...